<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Microvascular angina: Angina pectoris with normal coronary arteries</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Microvascular angina: Angina pectoris with normal coronary arteries</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Microvascular angina: Angina pectoris with normal coronary arteries</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Imran Chaudhary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A sizeable number of patients referred for evaluation of anginal symptoms and evidence of myocardial ischemia on noninvasive testing have angiographically normal epicardial coronary arteries or coronary arteries with mild atherosclerotic disease (ASCVD). In the past, this condition was labeled as cardiac syndrome X due to uncertainty about its pathogenesis. The more appropriate term, however, is microvascular angina (MVA). (See <a class="local">'Pathogenesis'</a> below.)</p><p>This topic will discuss the pathogenesis, clinical features, diagnosis, and treatment of microvascular angina. Related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1481.html" rel="external">"Vasospastic angina"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/100408.html" rel="external">"Myocardial infarction or ischemia with no obstructive coronary atherosclerosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115790.html" rel="external">"Mechanisms of acute coronary syndromes related to atherosclerosis"</a>.)</p><p></p><p class="headingAnchor" id="H352467332"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>The terms "MVA," "cardiac syndrome X," and "chest pain with normal coronary arteries" have been used interchangeably in the literature to describe patients with angina symptoms despite having angiographically normal coronary arteries. MVA is a more appropriate term to define patients with myocardial ischemia triggered by coronary microvascular dysfunction (CMD). Although MVA implies patients with no obstructive coronary artery disease (CAD), CMD can be also responsible for myocardial ischemia in patients with epicardial coronary artery disease. Thus, these conditions are not mutually exclusive, as MVA and CAD-related angina can coexist. The term ischemia with no obstructive coronary arteries (INOCA) is also gaining acceptance in the medical literature.</p><p>In this topic, the following definitions apply:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest pain with normal coronary arteries</strong> – This is the broadest term and is used to refer to anyone with angina-like chest pain and normal epicardial coronary arteries on coronary angiography. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MVA</strong> – Applies to any patient with angina and/or evidence of myocardial ischemia who is thought to have coronary microvascular dysfunction by either clinical presentation or confirmatory testing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microvascular disease (MVD) </strong>– This is another term for coronary microvascular disease and includes patients with MVA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>INOCA </strong>– Refers to ischemia with no obstructive coronary artery disease. In INOCA, the mismatch between blood supply and myocardial oxygen demands may be caused by CMD and/or epicardial coronary artery spasm (also known as vasospastic angina), typically in the setting of nonobstructive coronary atherosclerosis. Therefore, persons with INOCA can have angina from CMD and/or epicardial coronary artery spasm. This topic will address angina from CMD [<a href="#rid1">1</a>]. Vasospastic angina in discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1481.html" rel="external">"Vasospastic angina"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MINOCA </strong>– Refers to myocardial infarction with no obstructive coronary atherosclerosis. MINOCA is a clinical syndrome characterized by evidence of myocardial infarction (MI) with normal or near normal coronary arteries on angiography (stenosis severity ≤50 percent) in the absence of obvious noncoronary causes of MI, such as severe hemorrhage or severe respiratory failure. MINOCA is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/100408.html" rel="external">"Myocardial infarction or ischemia with no obstructive coronary atherosclerosis"</a> and  <a class="medical medical_review" href="/z/d/html/100408.html" rel="external">"Myocardial infarction or ischemia with no obstructive coronary atherosclerosis", section on 'Coronary microvascular dysfunction'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary MVA </strong>– Refers to MVA in the absence of underlying other coexisting conditions that underlie MVA pathogenesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary MVA </strong>– Refers to MVA secondary to coexisting conditions such as hypertension or diastolic dysfunction. (See <a class="local">'Secondary microvascular'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coronary microvascular dysfunction (CMD)</strong> – Abnormal vasodilatory capacity or intense vasoconstriction affecting smaller coronary arteries (less than 500 micrometers in diameter). These are prearterioles and arterioles that feed the capillaries and regulate myocardial blood flow. CMD is characterized by reduced coronary flow reserve (CFR), microvascular spasm, and/or coronary endothelial dysfunction. A clinical classification of CMD has been proposed [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CMD in the absence of obstructive CAD or other myocardial disease. This has been termed primary MVA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CMD in the presence of myocardial diseases. This has been termed secondary MVA. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CMD in the presence of obstructive CAD. This is a form of secondary MVA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Iatrogenic CMD. This may be seen after coronary revascularization and is caused by vasoconstriction or distal embolization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasospastic angina</strong> – Also known as "variant angina," this is spasm of epicardial coronary artery and is different from microvascular angina. It will not be discussed here. (See  <a class="medical medical_review" href="/z/d/html/1481.html" rel="external">"Vasospastic angina"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasoconstriction</strong> <strong>and vasospasm</strong> – These have been used interchangeably in the literature. For clarity, we use vasospasm to refer to the presence of <strong>epicardial</strong> arterial smooth muscle spasm that causes severe obstruction (&gt;80 to 90 percent arterial diameter reduction) and myocardial ischemia. We refer to <strong>microcirculatory</strong> vasoconstriction, as representing visible constriction distal to the epicardial coronary arteries [<a href="#rid3">3</a>], and "microvascular spasm" to refer to occlusive or subocclusive vasomotor changes in the coronary microvessels leading to myocardial ischemia [<a href="#rid4">4-6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coronary flow reserve (CFR) </strong>—<strong> </strong>A key component of both the pathophysiology and diagnosis of microvascular disease (MVD) is a reduction in CFR. CFR refers to the magnitude of increase in coronary flow (per unit of time) that can be achieved between basal coronary perfusion to maximum coronary vasodilation. It is expressed as ratio of blood flow during hyperemia to blood flow at rest. (See <a class="local">'Coronary flow reserve on angiography'</a> below.) </p><p></p><p class="headingAnchor" id="H262633435"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Several pathogenic features underlie microvascular disease (MVD), with a subset of patients having prominent vasoconstriction. Structural remodeling of coronary microvasculature occurs more frequently in persons with cardiovascular risk factors (eg, smoking, diabetes, atherosclerosis, and hypertension). Microvascular<strong> endothelial dysfunction</strong> from lower vasodilatory capacity of microvasculature and microvascular<strong> vasoconstriction</strong> from hypersensitivity to vasoconstrictor stimuli are key disease mechanisms. Anxiety was shown to be associated with microvascular endothelial dysfunction [<a href="#rid7">7</a>]. In addition, functional dysregulation in medium to large arterioles can cause <strong>paradoxical vasoconstriction</strong> when myocardial oxygen demands increase [<a href="#rid8">8</a>].</p><p>Other established and possible mechanisms for primary MVA:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral illness </strong>– In some patients, MVA is precipitated by an acute illness. Presentation of MVA after a viral infection is a relatively common scenario in our experience.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormonal mechanisms</strong> − Studies have shown that there is a higher proportion of females, especially postmenopausal, among patients referred for coronary angiography for evaluation of chest pain and positive stress test. This suggests hormonal mechanisms, possibly estrogen deficiency, as a possible contributing factor, but no studies have conclusively shown estrogen deficiency or hormonal imbalance as a definite cause of MVA [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammation </strong>–<strong> </strong>Studies suggest that<strong> </strong>inflammation may contribute to MVA and MVA severity: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with MVA, biomarkers of systemic inflammation are related to lower coronary flow reserve (CFR) [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High sensitivity C-relative protein correlates with a greater number of MVA symptoms and electrocardiogram (ECG) marker abnormalities [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MVA is associated with inflammatory diseases such as systemic lupus erythematosus and rheumatoid arthritis [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ectopic fat depots that exert paracrine inflammatory effects on adjacent tissues may be involved in MVA pathogenesis. In a retrospective study of 399 patients who underwent coronary angiography, epicardial adipose tissue was associated with coronary microvascular disease, independent of BMI (OR 1.30, 95% CI 1.00-1.70) [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autonomic dysfunction </strong>– Studies are mixed as to whether autonomic dysfunction contributes to MVD [<a href="#rid14">14</a>]. </p><p></p><p class="headingAnchor" id="H3537681832"><span class="h2">Secondary microvascular</span><span class="headingEndMark"> — </span>MVD secondary to other conditions has unique pathogenic mechanisms. For example, extramural compression can be present in conditions such as aortic valve stenosis, hypertrophic cardiomyopathy, or arterial hypertension. Pathogenic mechanisms for conditions that cause secondary MVA include the following: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microembolization in</strong> <strong>acute coronary syndrome </strong>– In the initial event or with recanalization, there can be microembolization causing luminal obstruction [<a href="#rid15">15,16</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Left ventricular hypertrophy (LVH) </strong>– Extramural compression can be present in conditions with LVH, such as aortic valve stenosis and arterial hypertension [<a href="#rid2">2</a>]. Abnormal CFR has been demonstrated in patients with left ventricular hypertrophy despite presence of angiographically normal coronary arteries. This occurs due to remodeling of vascular and extravascular structures and to coronary hemodynamics. This includes remodeling of intramural arterioles and interstitial fibrosis, which leads to a decreased density of vessels in the coronary microvasculature [<a href="#rid2">2</a>]. An imbalance between supply and demand is also an important determinant of myocardial ischemia in these patients. (See  <a class="medical medical_review" href="/z/d/html/1472.html" rel="external">"Approach to the patient with suspected angina pectoris"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Essential hypertension</strong> − Abnormal CFR has been demonstrated in patients with essential hypertension despite presence of angiographically normal coronary arteries and absence of LVH. This has been attributed to remodeling of vascular and extravascular structures, capillary rarefaction, and to coronary hemodynamics [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aortic valve stenosis </strong>– MVA in patients with aortic stenosis is thought to be due to the development of LVH. There is reduced diastolic coronary perfusion time, perimyocytic fibrosis, and a reduction in the number of resistance vessels per unit of weight, which leads to reduced coronary flow reserve [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure with preserved ejection fraction (HFpEF)</strong> – The majority of patients with HFpEF have MVD. In a study of 202 patients with HFpEF without obstructive epicardial coronary artery disease, 75 percent had coronary flow reserve &lt;2.5 [<a href="#rid17">17</a>]. In another study of 62 patients with HFpEF, endothelium-independent MVD (defined as coronary flow reserve &lt;2 and/or index of microvascular resistance ≥25) was identified in 66 percent of participants [<a href="#rid18">18</a>]. Some patients studied had obstructive epicardial coronary disease. Indices of MVA, such as coronary flow reserve, are discussed elsewhere. (See <a class="local">'Additional invasive testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertrophic cardiomyopathy and dilated cardiomyopathy</strong> – MVA in this setting is due to widespread remodeling of intramural arterioles. Severity of coronary microvascular dysfunction in affected patients has been shown to be an independent predictor of cardiac events and mortality [<a href="#rid2">2</a>]. Hypertrophic cardiomyopathy can create extramural compression. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infiltrative heart disease </strong>− In conditions like Anderson-Fabry disease, there is severely blunted coronary flow reserve due to glycosphingolipid deposition in myocytes, conduction tissue and vascular endothelium leading to myocyte hypertrophy/fibrosis, endothelial dysfunction, and perivascular fibrosis [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/4914.html" rel="external">"Fabry disease: Cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1">Cardiac amyloidosis may cause patients to have angina despite angiographically normal coronary arteries. Coronary flow reserve is severely blunted in these patients, leading to MVA [<a href="#rid2">2</a>]. Occasional patients with angina and angiographically normal coronary arteries (5 of 153 in one report) have underlying systemic amyloidosis in which the chest pain may result from amyloid deposits in the intramyocardial coronary arteries [<a href="#rid19">19,20</a>]. The diagnosis of amyloidosis may not be made for several years after the onset of chest pain, usually due to the development of kidney disease or heart failure. (See  <a class="medical medical_review" href="/z/d/html/122846.html" rel="external">"Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rheumatologic disease </strong>–<strong> </strong>Both systemic lupus erythematosus and rheumatoid arthritis are more prevalent in patients with angina and coronary microvascular dysfunction [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H262634455"><span class="h2">Enhanced pain sensitivity</span><span class="headingEndMark"> — </span>In some patients with MVA, enhanced pain sensitivity (hyperalgesia or cardiac nociception abnormality) is an alternative explanation for chest pain [<a href="#rid21">21,22</a>]. This hypothesis is indirectly supported by studies that could not demonstrate evidence of ischemia in patients with typical chest pain and coronary microvascular dysfunction after stresses such as exercise, <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>, <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a>, or transesophageal atrial pacing. Despite the frequent provocation of chest pain with these stresses, some patients do not have perfusion defects, regional wall motion abnormalities, or a decline in left ventricular function or myocardial blood flow [<a href="#rid23">23-26</a>]. It has been suggested that in the presence of increased pain perception/reduced pain threshold (eg, as a result of estrogen deficiency), minor degrees of subendocardial ischemia, patchy foci of reduced blood flow in the subendocardium, or even a marked redistribution of intramyocardial blood flow may result in severe chest discomfort in some patients.</p><p></p><p>In addition, in patients with this "hyperalgesia syndrome," chest pain can be provoked in the cath lab by moving the catheter within the right atrium or the right ventricle, without evidence of myocardial ischemia [<a href="#rid27">27</a>]. It has been suggested that this type of hyperalgesia may result from sympathovagal imbalance with sympathetic predominance [<a href="#rid28">28</a>] or reduced activity of the endogenous opioid system [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>MVA is common. A meta‐analysis of 56 studies of over 14,400 patients with suspected coronary disease and no epicardial obstructive coronary lesions showed the prevalence of MVA is 41 percent (95% CI 36–47 percent) [<a href="#rid30">30</a>]. The following demographic and clinical risk factors for MVA have been identified: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Younger age </strong>– Patients with MVA are younger at the time of diagnosis (mean age 49 years) and are more often female than those with atherosclerotic cardiovascular disease (ASCVD) in most [<a href="#rid23">23,31,32</a>] but not all series [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Female sex </strong>– The following studies highlight the relationship between female sex and MVA:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Myocardial ischemia and/or coronary microvascular dysfunction (CMD) is present in 20 to 50 percent of females with chest pain and normal coronary arteries [<a href="#rid34">34-38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a study of 886 patients referred for angiographic evaluation of chest pain, normal coronary arteries were found in 41 percent of the females compared with only 8 percent of the males (16 percent overall) [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar findings were noted in a series of 323 females (mean age 59) with suspected or possible ischemic chest pain: 37 percent had normal coronary arteries (less than 20 percent stenosis) [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Traditional cardiovascular risk factors </strong>–<strong> </strong>These are found more often in patients with MVA than in the general population [<a href="#rid40">40</a>]. Diabetes mellitus is often associated with microvascular disease (MVD). Cigarette smoking has been associated with MVD, and coronary flow reserve may be reduced by up to 21 percent in these patients [<a href="#rid2">2</a>]. Reductions in coronary flow reserve have also been observed in asymptomatic subjects with hypercholesterolemia and angiographically normal coronary arteries. (See  <a class="medical medical_review" href="/z/d/html/1538.html" rel="external">"Coronary artery endothelial dysfunction: Basic concepts", section on 'Diabetes mellitus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anxiety </strong>– In a single-institution retrospective study of 1974 patients who underwent invasive coronary reactivity testing for angina and were evaluated for anxiety, anxiety disorders were significantly more common in patients with any type of coronary endothelial dysfunction (OR 1.36, 95% CI 1.10-1.68) [<a href="#rid7">7</a>]. Among patients with anxiety, there was a higher prevalence of coronary endothelial dysfunction (62.7 versus 56.4 percent). After stratifying by sex, anxiety was related to coronary endothelial dysfunction in females but not in males.</p><p></p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Most patients with MVA-related chest discomfort are evaluated for obstructive coronary artery disease, given that the clinical presentation is often indistinguishable from that in patients with coronary artery disease (CAD)-related angina. A complete history, physical examination, resting electrocardiogram (ECG), and stress test are most often carried out in these patients and the diagnosis of MVA is usually considered after coronary angiography has been performed and has shown no significant epicardial coronary artery disease.</p><p class="headingAnchor" id="H352465069"><span class="h2">History</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angina characteristics </strong>– Most often, patients present with a chronic pattern of recurrent episodes of chest pain on effort that is similar to classic angina pectoris and others (less commonly) with angina at rest suggestive of coronary artery spasm. Some patients have atypical chest pain that is interpreted to be noncardiac. In some patients, chest pain may be severe and debilitating to a point where it affects daily activities [<a href="#rid32">32</a>]. The duration of chest pain episodes is often prolonged compared with that with effort angina [<a href="#rid32">32</a>]. Some patients have dyspnea on exertion as the only manifestation of microvascular angina. Dyspnea is an established anginal equivalent in patients with obstructive coronary disease [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/1472.html" rel="external">"Approach to the patient with suspected angina pectoris"</a>.)</p><p></p><p class="bulletIndent1">There are four common clinical patterns of MVA that have different treatment approaches:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Effort-related angina – This occurs in about half of the patients with MVA [<a href="#rid26">26,42</a>]. (See <a class="local">'Initial therapy for effort angina'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rest angina – Often episodes occur in the early morning. Importantly, if rest angina is present (with or without effort angina), vasoconstriction is likely involved. (See <a class="local">'Initial therapy for rest or mixed angina'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mixed effort and rest angina. (See <a class="local">'Initial therapy for rest or mixed angina'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a minority of patients, MVA is precipitated by an acute illness such as a viral infection. After resolution of the illness, in our experience, the angina symptoms usually (but not always) become less troublesome. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduced exercise tolerance</strong> – Several studies have found that exercise capacity is reduced in patients with microvascular disease (MVD) [<a href="#rid43">43,44</a>], perhaps in part related to deconditioning. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute myocardial infarction </strong>–<strong> </strong>Some patients with MVA can present with an acute myocardial infarction. Support for the possible role of MVA as a cause of acute coronary syndrome (ACS) is the observation that normal coronary vessels or no vessel with ≥50 percent stenosis have been reported in approximately 9 to 14 percent of patients with a non-ST elevation ACS [<a href="#rid45">45-49</a>], but prevalence of MVA as a causal mechanism in this population is not known. (See  <a class="medical medical_review" href="/z/d/html/43.html" rel="external">"Acute coronary syndrome: Terminology and classification"</a> and  <a class="medical medical_review" href="/z/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction", section on 'Definitions'</a>.) </p><p></p><p class="headingAnchor" id="H7108261"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Although physical examination is very important in all patients with angina, there are no findings that are specific for MVA. However, during an episode, tachycardia, hypertension, diaphoresis, and an S3 or S4 may be heard. These exam findings are also seen in classic angina. (See  <a class="medical medical_review" href="/z/d/html/1079.html" rel="external">"Auscultation of heart sounds", section on 'Third (S3) and fourth (S4) heart sounds'</a>.)</p><p class="headingAnchor" id="H345894918"><span class="h2">Electrocardiogram</span><span class="headingEndMark"> — </span>A 12-lead ECG should be performed in all patients with a history of chest pain. The ECG is usually normal between episodes. Transient ECG changes, including ST-segment depression with anginal pain, are common [<a href="#rid50">50</a>], but the absence of ECG changes does not exclude a cardiac etiology, because of the low sensitivity of the ECG. ST-segment elevation that is the hallmark of vasospastic angina is not a feature of MVA [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/1481.html" rel="external">"Vasospastic angina", section on '12-lead ECG during chest pain'</a>.)</p><p>Ambulatory ECG monitoring for 24 hours may be helpful for documenting ST-segment changes.</p><p class="headingAnchor" id="H313224195"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Most patients with chest pain suspicious for myocardial ischemia undergo a noninvasive evaluation for both diagnostic and prognostic purposes. Once obstructive epicardial coronary artery disease has been ruled out with angiography or other testing, the diagnosis of MVA becomes more likely, and MVA-focused evaluation is performed. Therefore, having a high degree of suspicion can help in earlier identification of MVA. </p><p>It should be kept in mind that noncardiac causes of chest pain must be considered and potentially investigated before the diagnosis of MVA can be made.</p><p class="headingAnchor" id="H3205123544"><span class="h2">Initial noninvasive evaluation</span><span class="headingEndMark"> — </span>Most stable patients with chest pain that has characteristics of myocardial ischemia will be referred for stress testing with or without perfusion imaging, echocardiography, or coronary computed tomographic angiography [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/1534.html" rel="external">"Stress testing for the diagnosis of obstructive coronary heart disease"</a> and  <a class="medical medical_review" href="/z/d/html/1502.html" rel="external">"Selecting the optimal cardiac stress test"</a> and  <a class="medical medical_review" href="/z/d/html/5310.html" rel="external">"Overview of stress echocardiography"</a> and  <a class="medical medical_review" href="/z/d/html/1494.html" rel="external">"Exercise ECG testing: Performing the test and interpreting the ECG results"</a> and  <a class="medical medical_review" href="/z/d/html/5328.html" rel="external">"Overview of stress radionuclide myocardial perfusion imaging"</a> and  <a class="medical medical_review" href="/z/d/html/129395.html" rel="external">"Clinical use of coronary computed tomographic angiography"</a>.)</p><p>Some information is known about the results of these noninvasive tests performed in individuals who are later given the diagnosis of MVA. If an exercise electrocardiogram (ECG) is used, the typical finding in patients with MVA is horizontal or downsloping ST-segment depression, as seen in patients with obstructive coronary artery disease (CAD). Exercise stress myocardial perfusion scintigraphy may demonstrate regional myocardial perfusion defects during exercise [<a href="#rid53">53,54</a>]. However, some reports have demonstrated neither perfusion defects nor regional wall motion abnormalities after <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> or transesophageal atrial pacing, despite the frequent provocation of chest pain [<a href="#rid23">23,24</a>]. It is possible that ischemia is limited to the subendocardium, or is "patchy" in character, which could explain the absence of wall motion abnormalities as assessed by echocardiography [<a href="#rid55">55</a>] (see <a class="local">'Additional invasive testing'</a> below). Some studies have found that exercise perfusion imaging demonstrates evidence of left ventricular systolic and diastolic dysfunction, which is consistent with ischemia [<a href="#rid56">56</a>], while others have not [<a href="#rid23">23-25</a>].</p><p>Some patients are referred for computed tomography angiography rather than coronary angiography when their first noninvasive test gives a low or intermediate probability result. Patients with possible MVA will not have coronary artery stenoses of more than 50 percent. (See  <a class="medical medical_review" href="/z/d/html/5308.html" rel="external">"Cardiac imaging with computed tomography and magnetic resonance in the adult"</a>.)</p><p>Finally, some patients are evaluated at the time of an anginal episode and are given sublingual <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> (NTG) both as a diagnostic test and to relieve symptoms due to angina. In MVA, as the small arterioles are less directly affected by the vasodilatory effects of NTG compared with the epicardial arteries, the drug may not be reliably effective [<a href="#rid57">57</a>]. Thus, when a patient is felt to have angina but does not respond rapidly to NTG, MVA should be considered. However, it should be kept in mind that the absence of response to NTG has a low predictive value for MVA.</p><p class="headingAnchor" id="H245998159"><span class="h2">Diagnostic coronary angiography</span><span class="headingEndMark"> — </span>In some patients with chest pain, coronary angiography is indicated for further diagnostic testing or as a prelude to revascularization. In patients with MVA, the coronary angiogram will show normal epicardial coronary arteries or mild coronary artery disease (&lt;30 percent stenosis). In patients with lesions between 30 and 50 percent, further evaluation with fractional flow reserve should be carried out to make sure that the lesion(s) is not hemodynamically significant. (See  <a class="medical medical_review" href="/z/d/html/1514.html" rel="external">"Clinical use of coronary artery pressure flow measurements"</a> and  <a class="medical medical_review" href="/z/d/html/16536.html" rel="external">"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation", section on 'Ultrasonic image of an atherosclerotic plaque'</a>.)</p><p class="headingAnchor" id="H965698439"><span class="h2">Additional invasive testing</span><span class="headingEndMark"> — </span>For patients without obstructive CAD as the cause of myocardial ischemia and in whom the diagnosis of MVA is considered, additional testing, usually performed at the time of coronary angiography, may be helpful. Local availability and expertise will dictate which test is chosen, and it may be necessary to perform more than one to establish the diagnosis of MVA due to heterogeneity of underlying mechanisms. If these tests are not available, the clinical presentation can be used as an indication that vasoconstriction is present and can help direct therapy. (See <a class="local">'History'</a> above.)</p><p class="headingAnchor" id="H3467066645"><span class="h3">Coronary flow reserve on angiography</span><span class="headingEndMark"> — </span>Measurement of coronary flow reserve (CFR) during invasive coronary angiography using a Doppler flow wire to measure coronary blood velocity reserve or pressure/thermodilution wire to measure coronary blood flow reserve can be useful [<a href="#rid58">58,59</a>]. CFR is the ratio of maximal hyperemic coronary blood flow measured after infusion of a coronary vasodilator, such as <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>, to resting, or basal coronary blood flow. Normal CFR ranges from 2.5 to 5; occasionally, it is greater than 5. Maximal coronary blood flow should be at least two and a half times the resting blood flow. When there is no significant epicardial coronary artery disease, CFR shows the degree of resistance to blood flow in the microcirculation. It can be measured invasively using a Doppler wire placed into the coronary artery, and then infusing adenosine either intravenously or directly into the coronary artery [<a href="#rid2">2</a>]. CFR values below or equal to 2 or 2.5, depending on methodology used, are indicative of coronary microvascular dysfunction [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/1514.html" rel="external">"Clinical use of coronary artery pressure flow measurements"</a>.)</p><p class="headingAnchor" id="H2785522912"><span class="h3">Coronary microvascular vasoconstriction</span><span class="headingEndMark"> — </span>Coronary microvascular vasoconstriction (different from focal epicardial coronary artery spasm) can be detected during angiographic studies in patients with chest pain despite angiographically normal coronary arteries using intracoronary acetylcholine (Ach) testing [<a href="#rid4">4</a>]. Ach produces coronary vasodilation in presence of healthy endothelium and paradoxical vasoconstriction in the presence of endothelial dysfunction.</p><p>At least two studies of patients with chest pain and nonobstructive coronary artery disease (all lesions &lt;50 percent diameter stenosis) have demonstrated the potential use of intracoronary acetylcholine for the diagnosis of MVA [<a href="#rid61">61,62</a>]. In a study of 921 patients who underwent diagnostic coronary angiography for suspected myocardial ischemia and who did not have high-grade coronary stenoses, 847 underwent testing with relatively high-dose Ach [<a href="#rid62">62</a>]. Microvascular vasoconstriction (angina and ischemic ECG shifts without epicardial spasm) was found in about one-quarter. No fatal or irreversible nonfatal complications occurred [<a href="#rid63">63</a>].</p><p>In an Ach test, incremental doses of intracoronary Ach are administered over three minutes until response is produced or target dose is reached. </p><p class="bulletIndent1"><span class="glyph">●</span>Positive response for epicardial coronary spasm is &gt;75 percent focal or diffuse coronary artery diameter reduction (compared with relaxed state). Patients have reproduction of angina and ischemic ECG changes. These patients will be considered to have vasospastic angina, not MVA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive response for microvascular vasoconstriction is absence of epicardial coronary spasm (&lt;75 percent diameter reduction). Patients have reproduction of angina and ischemic ECG changes (ST depression or ST elevation 0.1 mV in two contiguous leads). These patients will be considered to have MVA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Negative response to Ach test is absence of epicardial coronary spasm (no or &lt;75 percent diameter reduction), no angina, and no ischemic ECG changes. These patients are further evaluated with intracoronary <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>.</p><p></p><p class="headingAnchor" id="H1530371270"><span class="h3">Adenosine test</span><span class="headingEndMark"> — </span>We further evaluate patients who have a "negative" response to Ach with intracoronary <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>. In adenosine test, bolus adenosine doses (18 micrograms in left coronary artery and 12 micrograms in right coronary artery) are injected into the coronary arteries followed by 5 mL <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> solution flush. Coronary flow velocities (CFVs) are measured using sensor-tipped guidewire (with either a Doppler probe or thermistor/pressure sensor). CFR is calculated from CFVs (ratio of peak CFV to baseline CFV). CFR &lt;2.5 indicates endothelium-independent coronary microvascular dysfunction. These patients with abnormal CFR will also be considered to have MVA [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H2012173922"><span class="h2">Noninvasive testing</span><span class="headingEndMark"> — </span>The following noninvasive tests may be used in patients who are not able to undergo the invasive tests described above or who do not have a clear diagnosis after completion of an invasive evaluation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Computed tomography fractional flow reserve </strong>– Fractional flow reserve can be estimated from a computed tomography-derived model of the coronary circulation, which is based on computational fluid dynamic principles [<a href="#rid65">65,66</a>]. This method does not require a vasodilator or physiologic stress.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positron emission tomography coronary flow reserve </strong>–<strong> </strong>Positron emission tomography images can provide an estimate of coronary flow reserve by comparing myocardial blood flow at rest with blood flow acquired during stress [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular magnetic resonance imaging coronary flow reserve</strong> – Cardiovascular magnetic resonance imaging provides a measure of coronary flow reserve (ie, myocardial perfusion reserve index) by comparing perfusion (first-pass gadolinium uptake) at rest with perfusion during vasodilator or <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress [<a href="#rid67">67,68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiographic coronary flow reserve </strong>– Echocardiographic coronary flow reserve is measured by comparing velocities obtained from the left anterior descending artery at rest with velocities obtained during stress [<a href="#rid69">69</a>]. Echocardiographic myocardial perfusion reserve is measured by comparing contrast echocardiography-derived myocardial replenishment curves obtained at rest with curves obtained with peak <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> infusion.</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Our criteria for establishing the diagnosis of MVA are in accord with the criteria established by the Coronary Vasomotion Disorders International Study Group (COVADIS) [<a href="#rid70">70</a>] and are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical features consistent with the diagnosis. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Objective documentation of myocardial ischemia. (See <a class="local">'Initial noninvasive evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of obstructive coronary artery lesions on coronary angiography. (See <a class="local">'Diagnostic coronary angiography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Completion of an intracoronary evaluation with measurement of fractional flow reserve as well as acetylcholine and <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> testing. (See <a class="local">'Additional invasive testing'</a> above.)</p><p></p><p class="bulletIndent1">In lieu of this intracoronary evaluation, patients who are given a clinical diagnosis of MVA are treated as discussed below (see <a class="local">'Management'</a> below). Patients who do not respond should be referred for further invasive or noninvasive diagnostic testing. (See <a class="local">'Additional invasive testing'</a> above and <a class="local">'Noninvasive testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar to the evaluation of all patients with chest pain, noncardiac causes should be considered and potentially investigated before the diagnosis of MVA can be given.</p><p></p><p>COVADIS<strong> </strong>has proposed the following clinical criteria for suspecting MVA (definitive MVA diagnosed if all four criteria are present) [<a href="#rid70">70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of myocardial ischemia. Effort and/or rest angina or angina equivalent (eg, dyspnea).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Objective evidence of myocardial ischemia. Ischemic electrocardiographic (ECG) changes during an episode of chest pain, stress-induced chest pain, and/or ischemic ECG changes, and/or presence of transient/reversible abnormal myocardial perfusion or wall motion abnormality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of obstructive coronary artery disease (CAD) (&lt;50 percent stenosis or fractional flow reserve &gt;0.8) by coronary computed tomography angiogram or invasive coronary angiography. An important clarification to this criterion is that the fractional flow reserve (FFR) is &gt;0.8 despite or in the absence of obstructive CAD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of impaired coronary microvascular function:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Impaired coronary flow reserve (CFR) (&lt;2 to &lt;2.5). (See  <a class="medical medical_review" href="/z/d/html/1514.html" rel="external">"Clinical use of coronary artery pressure flow measurements"</a> and <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coronary microvascular vasoconstriction. Reproduction of symptoms; ischemic ECG changes but no epicardial vasospasm during acetylcholine testing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal coronary microvascular resistance indices (eg, index of microcirculatory resistance &gt;25).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coronary slow flow phenomenon. TIMI frame count &gt;25.</p><p></p><p class="headingAnchor" id="H3925588460"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Securing the diagnosis of MVA is challenging<strong> </strong>[<a href="#rid71">71</a>]. Ideally, patients should be investigated for MVA at the time of diagnostic angiography, with the assessment of CFR and other coronary physiology techniques. We have found the following approach to be applicable to many patients in whom coronary angiography has not found epicardial coronary artery disease sufficient to explain the presence of myocardial ischemia. </p><p class="bulletIndent1"><span class="glyph">●</span>When a subcritical or intermediate coronary lesion is documented, FFR is used to exclude functional significance (FFR value &gt;0.8 indicates that the lesion is not functionally significant).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If significant epicardial coronary artery stenoses are excluded with FFR, acetylcholine (Ach) testing is performed to rule out epicardial coronary spasm and microvascular endothelial dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When epicardial coronary spasm and microvascular endothelial dysfunction are both excluded with Ach test, presence of endothelium independent microvascular dysfunction is ruled out using <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> test.</p><p></p><p class="headingAnchor" id="H628038095"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for MVA consists primarily of obstructive coronary artery disease, vasospastic angina and other causes of ischemia with nonobstructive coronary arteries (INOCA), and other conditions that cause chest pain. These are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1481.html" rel="external">"Vasospastic angina", section on 'Differential diagnoses'</a>.)</p><p>Diseases that cause secondary MVA must also be considered and treated. (See <a class="local">'Secondary microvascular'</a> above.)</p><p>Patients with right ventricular hypertrophy due to pulmonary hypertension may also have anginal symptoms. (See  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>For the majority of patients, primary MVA is a chronic condition that usually can be managed with lifestyle changes and pharmacotherapy but does not completely resolve. Accordingly, we have early and frequent discussions with our patients with MVA in which we explain the mechanisms responsible for their anginal pain and ways of dealing with a condition that is unlikely to completely resolve. We discuss that at times the angina will get worse and at times it will improve or be better controlled. </p><p>Contrary to initial belief, MVA is not necessarily a benign condition. Patients with primary and secondary MVA may have a poorer prognosis and more adverse cardiovascular events than the general population. Evidence of this includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, impaired coronary flow reserve (CFR) was independently associated with diastolic dysfunction and hospitalization from heart failure with preserved ejection fraction in patients undergoing evaluation for suspected coronary artery disease who did not have flow-limiting coronary artery disease or reduced left ventricular ejection fraction [<a href="#rid72">72</a>]. (See <a class="local">'Additional invasive testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, patients with stable angina referred for coronary angiography who had normal coronary arteries or diffuse nonobstructive coronary artery disease had a higher risk of major adverse cardiovascular events (cardiovascular mortality and hospitalization for myocardial infarction, heart failure, and stroke) and all-cause mortality compared with asymptomatic patients [<a href="#rid73">73</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional studies showed that coronary microvascular dysfunction (CMD), as measured by CFR, may identify patients at higher risk of cardiovascular mortality [<a href="#rid74">74</a>], and it is a stronger independent predictor of cardiovascular mortality than absolute maximal myocardial blood flow beyond traditional cardiovascular risk factors [<a href="#rid75">75</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Impaired CFR with preserved maximal myocardial blood flow identified patients at higher risk of cardiovascular mortality despite lack of myocardial ischemia [<a href="#rid75">75</a>]. These patients may be an appropriate target for initiation or intensification of lifestyle or pharmacologic preventive therapies for cardiovascular risk reduction. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preserved CFR, even in the presence of impaired maximal myocardial blood flow, identified low-risk patients (&lt;1 percent annual cardiovascular mortality risk) [<a href="#rid75">75</a>]. CMD has been associated with more adverse outcomes and poorer prognosis [<a href="#rid33">33,73</a>]. It is unclear if treatment directed toward CMD improves prognosis of these patients.</p><p></p><p>In the subset of patients with MVA and an acute coronary syndrome, the outcome is not benign but better than in those with a culprit coronary lesion [<a href="#rid46">46,47,76</a>]. This was best illustrated in the PURSUIT trial of 5767 patients with unstable angina or a non-ST elevation myocardial infarction; 6 percent had mild coronary disease (&gt;0 to ≤50 percent stenosis) and 6 percent had no disease [<a href="#rid47">47</a>]. The patients with no or mild coronary disease had a much lower rate of death or nonfatal myocardial infarction at 30 days than those with significant disease (2 and 6 versus 17 percent). </p><p>An international study of 686 patients with MVA showed that cardiac events (eg, unstable angina, cardiovascular disease, myocardial infarction, and heart failure) did not differ by sex or race/ethnicity (ie, White, Japanese, Hispanic, Black) [<a href="#rid77">77</a>]. Among persons with MVA, a history of prior coronary artery disease (HR 2.03, 95% CI 1.31-3.15) and hypertension (HR 1.69, 95% CI 1.07-2.68) were each associated with increased cardiovascular events. Females with MVA reported lower angina-related quality of life compared with males (quality of life was measured with the Seattle Angina Questionnaire [<a href="#rid78">78</a>]).</p><p class="headingAnchor" id="H19"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Unlike patients with chronic stable angina from obstructive coronary disease, patients with primary microvascular disease (MVD) are not candidates for revascularization and their treatment algorithms for angina differ according to their specific MVA history. A practical therapeutic approach is depicted in an algorithm  (<a class="graphic graphic_algorithm graphicRef138627" href="/z/d/graphic/138627.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3204351248"><span class="h2">Goals of treatment</span><span class="headingEndMark"> — </span>For all patients with MVA,<strong> </strong>we have three main treatment goals:</p><p class="bulletIndent1"><span class="glyph">●</span>To prevent and treat angina.</p><p class="bulletIndent1"><span class="glyph">●</span>To get patients to their desired level of exercise tolerance.</p><p class="bulletIndent1"><span class="glyph">●</span>To prevent long-term atherosclerotic cardiovascular disease and related adverse outcomes.</p><p></p><p>For most patients, in order to achieve their desired level of exercise tolerance, we need to first treat angina symptoms. </p><p class="headingAnchor" id="H2684317197"><span class="h2">General measures for all patients</span><span class="headingEndMark"> — </span>We suggest prescribing sublingual <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> (NTG) for all patients with MVA. We aggressively modify elevated atherosclerotic cardiovascular disease (ASCVD) risk factors and prescribe regular exercise. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">Nitroglycerin</a><strong> </strong>–<strong> </strong>Patients should be given a prescription for sublingual NTG, which can be used to relieve or prevent angina. Sublingual NTG is not effective for all patients with MVA. One study showed improvement with sublingual nitrates in about 40 percent of patients with MVD [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/1549.html" rel="external">"Nitrates in the management of chronic coronary syndrome", section on 'Sublingual nitroglycerin'</a>.)</p><p></p><p>Patients can also take long-acting nitrate therapy (in either a pill or patch formulation). Studies of long-acting nitrate therapy on relieving angina in MVD have yielded mixed results. A study of oral <a class="drug drug_general" data-topicid="8581" href="/z/d/drug information/8581.html" rel="external">isosorbide mononitrate</a> in MVD did not demonstrate efficacy [<a href="#rid79">79</a>]. Even though no randomized control trials have shown a clear benefit, they are widely used in patients with angina and normal coronary arteries. NTG patch at a dose of 0.2 to 0.4 mg/hour may be added to beta blocker or calcium channel blocker and may be effective at relieving angina. </p><p>If long-acting <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> therapy is effective in reducing a patient's MVA symptoms, we continue daily therapy. If long-acting nitroglycerin is not effective in relieving MVA, we stop it and prescribe other medication.</p><p class="bulletIndent1">In patients with effort-induced angina and a good response to nitrates, one approach we use is to have the patient apply a <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> patch 30 to 45 minutes before they undertake an activity known to trigger usual chest pain. The patch can be removed shortly after the end of the activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ASCVD prevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary ASCVD prevention </strong>–<strong> </strong>Patients with MVA who have modifiable risk factors for ASCVD (ie, hypertension, diabetes, dyslipidemia, obesity, smoking) should be treated with aggressive risk factor reduction, including lifestyle changes and pharmacotherapy, as indicated. (See  <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.) </p><p></p><p class="bulletIndent2">Hypertension should be treated to goal blood pressure. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p class="bulletIndent2">We prefer an angiotensin-converting enzyme (ACE) inhibitor for blood pressure control. Several studies demonstrate a potential benefit of therapy with an ACE inhibitor in MVA [<a href="#rid80">80-82</a>]. As examples:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In one randomized trial, 45 patients with MVA were assigned to treatment with either <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> (10 mg daily) plus <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> (40 mg daily) or placebo [<a href="#rid82">82</a>]. After six months, patients treated with atorvastatin and ramipril had significant improvements in brachial artery flow-mediated vasodilation (a marker of endothelial function), exercise duration, and angina frequency compared with placebo. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a randomized trial of 61 females with MVA as part of the Women's Ischemia Syndrome Evaluation study, women who received <a class="drug drug_general" data-topicid="9843" href="/z/d/drug information/9843.html" rel="external">quinapril</a> had improved coronary flow reserve (CFR) after 16 weeks compared with the placebo group [<a href="#rid81">81</a>]. In addition, the experimental group had improvement in angina symptoms based on the Seattle Angina Questionnaire [<a href="#rid78">78</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary ASCVD prevention </strong>– While there is no clear evidence for benefit of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in patients with microvascular dysfunction, many of these patients have multiple cardiovascular risk factors, and it is reasonable to prescribe aspirin 81 mg daily). (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'Prevention of cardiovascular disease events'</a>.) </p><p></p><p class="bulletIndent2">One of our contributors does not routinely prescribe statins for patients with MVA, unless there is another indication. However, another contributor does treat with statins as they have been shown to improve coronary artery endothelial function [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/z/d/html/4546.html" rel="external">"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease", section on 'Reversal of endothelial dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise </strong>–<strong> </strong>We routinely recommend a physical training program to improve exercise capacity and reduce the frequency of chest pain episodes. We refer patients with MVA to cardiac rehabilitation if their health insurance can cover the costs and/or the patient can pay the out-of-pocket costs. If the patient cannot participate in cardiac rehabilitation, we recommend regular symptom-limited exercise, with a gradual increase in duration and intensity as tolerated. (See  <a class="medical medical_review" href="/z/d/html/1477.html" rel="external">"Cardiac rehabilitation programs"</a> and  <a class="medical medical_review" href="/z/d/html/1552.html" rel="external">"Cardiac rehabilitation: Indications, efficacy, and safety in patients with coronary heart disease"</a>.)</p><p></p><p class="bulletIndent1">Exercise training may increase exercise capacity and relieve angina in patients with MVD. The potential benefit of physical training was demonstrated in a randomized trial including 26 patients with MVD [<a href="#rid43">43</a>]. Exercise training improved exercise capacity by 34 percent and delayed the onset of angina during exercise from 3±2 to 6±3 minutes. Addition of body awareness training to exercise therapy did not alter the pain response to exercise or affect maximal pain. </p><p></p><p class="headingAnchor" id="H3903160166"><span class="h2">Initial therapy for effort angina</span><span class="headingEndMark"> — </span>For patients who return with unacceptable effort-induced angina after one month of general therapy, further interventions are aimed at relief of angina [<a href="#rid22">22,32,84</a>]. Therapy is largely empiric, and optimal therapy may vary with the mechanism of MVA [<a href="#rid22">22</a>]. We suggest beta blockers as the initial therapy for most patients with persistent effort angina. (See <a class="local">'Combination therapy for persistent symptoms'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers </strong>–<strong> </strong>We use beta blockers for initial treatment of persistent effort-induced angina. We generally start with <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> succinate 50 mg daily and increase the dose to as much as 100 to 200 mg daily by one month if symptoms remain unacceptable. Metoprolol tartrate (same total daily dose given twice a day) may also be used in place of metoprolol succinate. <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">Bisoprolol</a> is an alternative (initial dose 2.5 mg daily and increase the dose to 10 mg daily if necessary). <a class="drug drug_general" data-topicid="9461" href="/z/d/drug information/9461.html" rel="external">Nebivolol</a> 5 mg daily is another choice. Although definitive controlled trials are not available, beta blockers seem to be most effective in reducing the frequency and severity of angina and in improving exercise tolerance [<a href="#rid79">79,85-87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative monotherapy for effort angina </strong>– For most patients with effort-induced angina and an intolerance to beta blockers, we suggest administering a calcium channel blocker. </p><p></p><p class="headingAnchor" id="H3005699613"><span class="h2">Initial therapy for rest or mixed angina</span><span class="headingEndMark"> — </span>Calcium channel blockers are the initial therapy in patients whose underlying pathogenetic mechanism includes microvascular vasoconstriction/vasospasm. (See <a class="local">'Coronary microvascular vasoconstriction'</a> above.)</p><p>We use extended-release <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> 180 mg daily and increase the dose at two- to four-week intervals to a maximum dose of 540 mg daily, as necessary. Short-acting calcium channel blockers should not be used, because of safety concerns. (See  <a class="medical medical_review" href="/z/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers"</a>.)</p><p class="bulletIndent1">The literature on the efficacy of calcium channel blockers for patients with MVD is conflicting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two small trials of 10 and 16 patients with MVD compared the effects of beta blockers and with those of calcium channel blockers and showed efficacy for beta blockers but not calcium channel blockers in reducing ischemic episodes [<a href="#rid79">79,85</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calcium channel blockers showed greater benefit in patients whose underlying pathogenetic mechanism is primarily microvascular vasoconstriction. (See <a class="local">'Coronary microvascular vasoconstriction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A study compared patients with documented coronary epicardial vasospasm with patients with microvascular dysfunction and found that half the patients with microvascular dysfunction showed symptomatic improvement with calcium channel blockers while almost all patients who were given a combination of calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors showed substantial relief of angina [<a href="#rid88">88</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A cohort study of 50 patients with MVD and microvascular vasoconstriction documented by invasive acetylcholine (Ach) testing evaluated symptoms after individuals took a calcium channel blocker [<a href="#rid61">61</a>]. Anginal episodes decreased in half of the patients, decreased substantially in 30 percent, and remained frequent in 20 percent of patients. This study is limited by lack of a control group. </p><p></p><p class="headingAnchor" id="H2048558746"><span class="h2">Combination therapy for persistent symptoms</span><span class="headingEndMark"> — </span>For most patients with persistent angina, we suggest adding an additional agent (ie, a beta blocker or calcium channel blocker as appropriate). If MVA symptoms persist, we add <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> and/or <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a>. Subsequent therapy for persistent angina is tailored based on the patient’s other comorbidities.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">Ranolazine</a> – This is a novel antianginal agent that is a late sodium current inhibitor. We start with the lowest available dose and titrate upwards as tolerated. In the United States, this would mean prescribing 500 mg twice daily; in other countries, it would mean prescribing 375 mg twice daily. </p><p></p><p class="bulletIndent1">In a study with crossover design of females with MVD diagnosed by cardiac magnetic resonance imaging perfusion, 20 individuals were randomly assigned to either <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> or placebo. After four weeks of therapy, ranolazine resulted in significantly better scores on the Seattle Angina Questionnaire and a trend toward improved myocardial perfusion [<a href="#rid89">89</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">Ivabradine</a><strong> </strong>–<strong> </strong>Ivabradine is a selective I<sub>f</sub> channel blocker that causes sinus bradycardia by inhibiting I<sub>f</sub> current in the sinus node. Unlike beta blockers, ivabradine does not cause vasoconstriction or have negative inotropic effects. We recommend starting at the lowest dose of 2.5 mg twice daily and increasing to 5 mg twice daily if needed for symptom relief. In a study, 46 patients with MVA were randomly assigned ivabradine, <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a>, and placebo and followed for angina symptoms, coronary microvascular dilation, exercise tolerance and ST-segment depression on stress testing [<a href="#rid90">90</a>]. Patients with ivabradine had improvement in angina symptoms when compared with the control group. However, there were no improvements in coronary microvascular dilation, exercise stress test duration, or time-to-ST-segment depression. Patients assigned ranolazine had greater improvement in angina, exercise duration, and time-to-ST-segment duration compared with the ivabradine or control groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">Imipramine</a> – For patients with depression or in whom hyperalgesia is suspected, and in whom further therapy is needed, we add imipramine. We suggest a starting dose of 25 mg at night. Patients sensitive to side effects and the older adults can start with a dose of 10 mg at bedtime. The dose can be increased by 25 to 50 mg every three to four days, as side effects allow, to a target dose range of 100 to 300 mg daily. Imipramine is a tricyclic antidepressant medication, which has been used successfully in the management of chronic pain syndromes. It may be effective in some patients with MVA when used at a low dose. One study evaluated 60 patients with chest pain and normal coronary angiograms [<a href="#rid91">91</a>]. Of these patients, 38 had one or more psychiatric disorders. The patients were randomly assigned to imipramine (50 mg nightly), <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a> (0.1 mg twice daily), or placebo. A benefit was seen only with imipramine, which reduced the frequency of chest pain in patients with MVA by approximately 50 percent. The psychiatric profile during treatment improved in all groups, and the benefit was seen in both males and females. In a separate, smaller crossover randomized controlled trial in 18 females with persistent angina, adding imipramine for five weeks resulted in lower angina scores [<a href="#rid92">92</a>]. In both studies, females reported a high burden of side effects with imipramine [<a href="#rid91">91,92</a>], which may have prevented any apparent improvement in quality of life. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> – In patients with MVA and metabolic syndrome or pre-/diabetes, metformin may be particularly helpful. There is no standard dosing regimen for metformin in MVD treatment. Studies have used a dose of 500 mg twice a day; we use 1 g daily. We would use it if there were persistent angina on initial therapy plus <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a>. However, we do not feel there is sufficient evidence to support its widespread use [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)", section on 'Prevention of type 2 diabetes'</a> and  <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">"Prevention of type 2 diabetes mellitus", section on 'Metformin'</a>.) </p><p></p><p class="headingAnchor" id="H2056037947"><span class="h2">Other therapy</span><span class="headingEndMark"> — </span>A subset of patients will not respond to general measures, initial, and/or combination therapy. In this case, the following medications have been useful in treating MVA but have little published evidence to support their use, and in the case of hormone replacement therapy, the risks may outweigh benefit.<strong> </strong></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">Sildenafil</a><strong> </strong>–<strong> </strong>(A phosphodiesterase 5 inhibitor) 25 mg daily has been used for relief of symptoms in patients with MVA when all other therapies have failed [<a href="#rid94">94</a>]. This intervention requires further study, but we consider it for treatment in refractory angina cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormone replacement therapy </strong>– Studies of hormone replacement therapy (HRT) have shown no definite cardioprotective effect, and, overall, HRT appears to increase the risk of coronary disease, stroke, venous thromboembolism, and breast cancer (see  <a class="medical medical_review" href="/z/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk"</a>). </p><p></p><p class="bulletIndent1">We do not routinely recommend HRT in postmenopausal females with MVA. However, there appears to be an association between anginal symptoms and estrogen deficiency in some women with postmenopausal symptoms and MVA. In these select women, it is reasonable to have a shared decision-making discussion about HRT between patient and providers with expertise in this area (either gynecologist or endocrinologist).</p><p></p><p class="headingAnchor" id="H83879271"><span class="h2">Management of refractory angina</span><span class="headingEndMark"> — </span>Patients who have inadequate response to the therapy above should be referred for confirmatory testing as described if not yet done. (See <a class="local">'Additional invasive testing'</a> above and <a class="local">'Noninvasive testing'</a> above.)</p><p></p><p>In the United States and elsewhere, many patients who present with anginal-quality chest pain and have no significant epicardial coronary artery do not undergo additional invasive confirmatory testing. A lack of expertise or equipment is often the explanation. </p><p>For patients who do not respond to treatment aimed at MVA, we recommend referring these patients to medical centers where these intracoronary tests can be performed or where a positron emission tomography scan and/or a cardiac magnetic resonance image perfusion scan are available to get a better understanding of the mechanism of MVA responsible for symptoms in a given patient. (See <a class="local">'Additional invasive testing'</a> above and <a class="local">'Noninvasive testing'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spinal cord stimulation </strong>– For patients in whom the diagnosis of MVA is confirmed and who have persistent unacceptable angina, we refer patients for evaluation for spinal cord stimulation. Spinal cord stimulation has been successful in the treatment of refractory angina due to coronary heart disease [<a href="#rid95">95</a>]. Spinal cord stimulation also improves angina and increases exercise tolerance in patients with refractory angina and normal coronary arteries [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/z/d/html/1524.html" rel="external">"New therapies for angina pectoris", section on 'Spinal cord stimulation'</a>.)</p><p></p><p>Other possible therapies for refractory angina with mixed or limited evidence:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enhanced external counter-pulsation (EECP) </strong>– This therapy is U S Food and Drug Administration approved for treatment of angina and used in some refractory MVA cases in the United States. EECP is not recommended by the National Institute for Health and Care Excellence in United Kingdom [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/z/d/html/1524.html" rel="external">"New therapies for angina pectoris", section on 'External counterpulsation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coronary sinus reduction </strong>– This surgical device has been studied for relief of refractory angina in patients with obstructive coronary disease; however, it has not been extensively tested in MVA. (See  <a class="medical medical_review" href="/z/d/html/1524.html" rel="external">"New therapies for angina pectoris", section on 'Coronary sinus reducing device'</a>.)</p><p></p><p class="bulletIndent1">In a preliminary study of eight patients, coronary sinus reduction was effective in reducing angina, increasing exercise tolerance, and improving ischemia on myocardial perfusion imaging tests [<a href="#rid98">98</a>]. However, larger randomized studies are needed prior to recommending this therapy for patients with MVA and refractory angina. </p><p></p><p class="headingAnchor" id="H2772414773"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115939.html" rel="external">"Society guideline links: Chronic coronary syndrome"</a>.)</p><p class="headingAnchor" id="H454739"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and epidemiology </strong>–<strong> </strong>Microvascular angina (MVA) refers to angina-like symptoms or ischemia in patients with normal coronary arteries. Patients with MVA are presumed or found to have microvascular dysfunction. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1">Compared with patients with obstructive coronary artery disease (CAD), patients with MVA are typically younger at the time of presentation, are more often female, and have a higher prevalence of anxiety and depression. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular risk</strong> –<strong> </strong>Most patients with MVA have a higher burden of classic cardiovascular disease (CVD) risk factors and are at higher risk of major adverse cardiac events compared with similar patients without MVA. (See <a class="local">'Prognosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In half of patients, MVA chest pain is similar to classic angina pectoris. The pain may be precipitated by effort but may also occur at rest, particularly in the presence of coronary microvascular spasm as a pathogenic mechanism. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other patients have chest pain and/or dyspnea thought to be noncardiac, which may be severe and debilitating to a point where it affects daily activities. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The duration of episodes of MVA is often prolonged compared with effort angina. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exercise capacity is often reduced in microvascular disease (MVD). (See  <a class="medical medical_review" href="/z/d/html/1472.html" rel="external">"Approach to the patient with suspected angina pectoris", section on 'Symptoms'</a> and <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of MVA is considered after coronary angiography has found that obstructive CAD is not the likely cause of chest pain. The diagnosis is definitively made by documentation of abnormal coronary microvascular response to functional testing with the reproduction of symptoms. In some patients, the diagnosis is made clinically. We assume that vasoconstriction is present in patients with rest angina or mixed rest/effort angina. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1">Diagnostic testing includes invasive and noninvasive testing aimed at detecting low coronary flow reserve, provoked microvascular spasm, and microvascular endothelial dysfunction. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>–<strong> </strong>The management<strong> </strong>of patients with confirmed or highly suspected MVA is depicted in a practical algorithm  (<a class="graphic graphic_algorithm graphicRef138627" href="/z/d/graphic/138627.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General measures</strong> – For all patients with MVA, we suggest prescribing sublingual <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> (NTG) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), which can be used for prevention or treatment of angina. For patients with effort angina, we also use an NTG patch prior to activity. Long-acting NTG can be tried but is not very effective for MVA treatment. We aggressively modify atherosclerotic cardiovascular disease (ASCVD) risk factors in particular, aggressively treating hypertension (ACE inhibitor is the preferred agent), secondary ASCVD prevention (where appropriate), and exercise. (See <a class="local">'Goals of treatment'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy for effort angina </strong>– For patients with MVA who have unacceptable effort-induced angina after one month of general measures, we suggest initial treatment with a beta blocker rather than other therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We start with <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> succinate 50 mg daily. Calcium channel blockers are a reasonable first choice for patients with an intolerance to beta blockers. (See <a class="local">'Initial therapy for effort angina'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy for rest or mixed angina</strong> – For patients with MVA with rest or mixed angina or documented vasoconstriction and who have unacceptable angina after one month of general measures, we suggest adding a calcium channel blocker (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combination therapy</strong> – For patients with persistent angina on initial therapy, we use combination therapy (ie, addition of beta blocker or calcium channel blocker). If there is persistent angina, we next add <a class="drug drug_general" data-topicid="10262" href="/z/d/drug information/10262.html" rel="external">ranolazine</a> and/or <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a>. For patients with persistent angina, we next add therapy based on patient comorbidities. (See <a class="local">'Combination therapy for persistent symptoms'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with depression or hyperalgesia, we add <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>. </p><p class="bulletIndent3"><span class="glyph">-</span>For patients with metabolic syndrome or prediabetes, we add <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other medications </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">Sildenafil</a> is an option for treatment of MVA though evidence of efficacy is not robust. (See <a class="local">'Other therapy'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We do not routinely use hormone replacement therapy (HRT) in postmenopausal women with MVA. (See <a class="local">'Other therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory angina </strong>– If all other therapies do not yield adequate treatment of MVA, a definitive diagnosis should be pursued if it has not been done, and spinal cord stimulation can be tried. (See <a class="local">'Management of refractory angina'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology &amp; Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 2020; 41:3504.</a></li><li><a class="nounderline abstract_t">Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356:830.</a></li><li><a class="nounderline abstract_t">Maseri A, Davies G, Hackett D, Kaski JC. Coronary artery spasm and vasoconstriction. The case for a distinction. Circulation 1990; 81:1983.</a></li><li><a class="nounderline abstract_t">Mohri M, Koyanagi M, Egashira K, et al. Angina pectoris caused by coronary microvascular spasm. Lancet 1998; 351:1165.</a></li><li><a class="nounderline abstract_t">Arrebola-Moreno AL, Arrebola JP, Moral-Ruiz A, et al. Coronary microvascular spasm triggers transient ischemic left ventricular diastolic abnormalities in patients with chest pain and angiographically normal coronary arteries. Atherosclerosis 2014; 236:207.</a></li><li><a class="nounderline abstract_t">Sun H, Mohri M, Shimokawa H, et al. Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol 2002; 39:847.</a></li><li><a class="nounderline abstract_t">Sara JDS, Ahmad A, Toya T, et al. Anxiety Disorders Are Associated With Coronary Endothelial Dysfunction in Women With Chest Pain and Nonobstructive Coronary Artery Disease. J Am Heart Assoc 2021; 10:e021722.</a></li><li><a class="nounderline abstract_t">Sorop O, van den Heuvel M, van Ditzhuijzen NS, et al. Coronary microvascular dysfunction after long-term diabetes and hypercholesterolemia. Am J Physiol Heart Circ Physiol 2016; 311:H1339.</a></li><li><a class="nounderline abstract_t">Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 2010; 55:2825.</a></li><li><a class="nounderline abstract_t">Schroder J, Mygind ND, Frestad D, et al. Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction. Int J Cardiol Heart Vasc 2019; 24:100370.</a></li><li><a class="nounderline abstract_t">Cosín-Sales J, Pizzi C, Brown S, Kaski JC. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol 2003; 41:1468.</a></li><li><a class="nounderline abstract_t">Recio-Mayoral A, Mason JC, Kaski JC, et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J 2009; 30:1837.</a></li><li><a class="nounderline abstract_t">Mahmoud I, Dykun I, Kärner L, et al. Epicardial adipose tissue differentiates in patients with and without coronary microvascular dysfunction. Int J Obes (Lond) 2021; 45:2058.</a></li><li><a class="nounderline abstract_t">Mittal SR. Etiopathogenesis of microvascular angina: caveats in our knowledge. Indian Heart J 2014; 66:678.</a></li><li><a class="nounderline abstract_t">Uren NG, Crake T, Lefroy DC, et al. Delayed recovery of coronary resistive vessel function after coronary angioplasty. J Am Coll Cardiol 1993; 21:612.</a></li><li><a class="nounderline abstract_t">Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J 2014; 35:1101.</a></li><li><a class="nounderline abstract_t">Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 2018; 39:3439.</a></li><li><a class="nounderline abstract_t">Rush CJ, Berry C, Oldroyd KG, et al. Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 2021; 6:1130.</a></li><li><a class="nounderline abstract_t">Al Suwaidi J, Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med 1999; 131:838.</a></li><li><a class="nounderline abstract_t">Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000; 109:181.</a></li><li><a class="nounderline abstract_t">Panza JA. Myocardial ischemia and the pains of the heart. N Engl J Med 2002; 346:1934.</a></li><li><a class="nounderline abstract_t">Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). Circulation 2004; 109:568.</a></li><li><a class="nounderline abstract_t">Panza JA, Laurienzo JM, Curiel RV, et al. Investigation of the mechanism of chest pain in patients with angiographically normal coronary arteries using transesophageal dobutamine stress echocardiography. J Am Coll Cardiol 1997; 29:293.</a></li><li><a class="nounderline abstract_t">Anselmi M, Golia G, Marino P, et al. Comparison of left ventricular function and volumes during transesophageal atrial pacing combined with two-dimensional echocardiography in patients with syndrome X, atherosclerotic coronary artery disease, and normal subjects. Am J Cardiol 1997; 80:1261.</a></li><li><a class="nounderline abstract_t">Nihoyannopoulos P, Kaski JC, Crake T, Maseri A. Absence of myocardial dysfunction during stress in patients with syndrome X. J Am Coll Cardiol 1991; 18:1463.</a></li><li><a class="nounderline abstract_t">Rosen SD, Uren NG, Kaski JC, et al. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation 1994; 90:50.</a></li><li><a class="nounderline abstract_t">Shapiro LM, Crake T, Poole-Wilson PA. Is altered cardiac sensation responsible for chest pain in patients with normal coronary arteries? Clinical observation during cardiac catheterisation. Br Med J (Clin Res Ed) 1988; 296:170.</a></li><li><a class="nounderline abstract_t">Cannon RO 3rd. The sensitive heart. A syndrome of abnormal cardiac pain perception. JAMA 1995; 273:883.</a></li><li><a class="nounderline abstract_t">Fedele F, Agati L, Pugliese M, et al. Role of the central endogenous opiate system in patients with syndrome X. Am Heart J 1998; 136:1003.</a></li><li><a class="nounderline abstract_t">Mileva N, Nagumo S, Mizukami T, et al. Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta-Analysis. J Am Heart Assoc 2022; 11:e023207.</a></li><li><a class="nounderline abstract_t">Sullivan AK, Holdright DR, Wright CA, et al. Chest pain in women: clinical, investigative, and prognostic features. BMJ 1994; 308:883.</a></li><li><a class="nounderline abstract_t">Kaski JC, Rosano GM, Collins P, et al. Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol 1995; 25:807.</a></li><li><a class="nounderline abstract_t">Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation 2014; 129:2518.</a></li><li><a class="nounderline abstract_t">Buchthal SD, den Hollander JA, Merz CN, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000; 342:829.</a></li><li><a class="nounderline abstract_t">Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109:2993.</a></li><li><a class="nounderline abstract_t">Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001; 141:735.</a></li><li><a class="nounderline abstract_t">Masci PG, Laclaustra M, Lara JG, Kaski JC. Brachial artery flow-mediated dilation and myocardial perfusion in patients with cardiac syndrome X. Am J Cardiol 2005; 95:1478.</a></li><li><a class="nounderline abstract_t">Atmaca Y, Ozdemir AO, Ozdol C, et al. Angiographic evaluation of myocardial perfusion in patients with syndrome X. Am J Cardiol 2005; 96:803.</a></li><li><a class="nounderline abstract_t">Merz CN, Kelsey SF, Pepine CJ, et al. The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. J Am Coll Cardiol 1999; 33:1453.</a></li><li><a class="nounderline abstract_t">Gulati M, Cooper-DeHoff RM, McClure C, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med 2009; 169:843.</a></li><li><a class="nounderline abstract_t">Abidov A, Rozanski A, Hachamovitch R, et al. Prognostic significance of dyspnea in patients referred for cardiac stress testing. N Engl J Med 2005; 353:1889.</a></li><li><a class="nounderline abstract_t">Kaski JC, Crea F, Nihoyannopoulos P, et al. Transient myocardial ischemia during daily life in patients with syndrome X. Am J Cardiol 1986; 58:1242.</a></li><li><a class="nounderline abstract_t">Eriksson BE, Tyni-Lennè R, Svedenhag J, et al. Physical training in Syndrome X: physical training counteracts deconditioning and pain in Syndrome X. J Am Coll Cardiol 2000; 36:1619.</a></li><li><a class="nounderline abstract_t">Bechsgaard DF, Hove JD, Suhrs HE, et al. Women with coronary microvascular dysfunction and no obstructive coronary artery disease have reduced exercise capacity. Int J Cardiol 2019; 293:1.</a></li><li><a class="nounderline abstract_t">Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 2006; 166:1391.</a></li><li><a class="nounderline abstract_t">Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol 1994; 74:531.</a></li><li><a class="nounderline abstract_t">Roe MT, Harrington RA, Prosper DM, et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation 2000; 102:1101.</a></li><li><a class="nounderline abstract_t">Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 2002; 288:3124.</a></li><li><a class="nounderline abstract_t">Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354:708.</a></li><li><a class="nounderline abstract_t">Lanza GA, Manzoli A, Pasceri V, et al. Ischemic-like ST-segment changes during Holter monitoring in patients with angina pectoris and normal coronary arteries but negative exercise testing. Am J Cardiol 1997; 79:1.</a></li><li class="breakAll">Maseri, A. Ischemic Heart Disease, Churchill Livingstone, United Kingdom 1995. p.507.</li><li><a class="nounderline abstract_t">Writing Committee Members, Gulati M, Levy PD, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Cardiovasc Comput Tomogr 2022; 16:54.</a></li><li><a class="nounderline abstract_t">Cannon RO 3rd, Camici PG, Epstein SE. Pathophysiological dilemma of syndrome X. Circulation 1992; 85:883.</a></li><li><a class="nounderline abstract_t">Fragasso G, Rossetti E, Dosio F, et al. High prevalence of the thallium-201 reverse redistribution phenomenon in patients with syndrome X. Eur Heart J 1996; 17:1482.</a></li><li><a class="nounderline abstract_t">Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002; 346:1948.</a></li><li><a class="nounderline abstract_t">Cannon RO 3rd, Bonow RO, Bacharach SL, et al. Left ventricular dysfunction in patients with angina pectoris, normal epicardial coronary arteries, and abnormal vasodilator reserve. Circulation 1985; 71:218.</a></li><li><a class="nounderline abstract_t">Kanatsuka H, Eastham CL, Marcus ML, Lamping KG. Effects of nitroglycerin on the coronary microcirculation in normal and ischemic myocardium. J Cardiovasc Pharmacol 1992; 19:755.</a></li><li><a class="nounderline abstract_t">Barbato E, Aarnoudse W, Aengevaeren WR, et al. Validation of coronary flow reserve measurements by thermodilution in clinical practice. Eur Heart J 2004; 25:219.</a></li><li><a class="nounderline abstract_t">Lee BK, Lim HS, Fearon WF, et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation 2015; 131:1054.</a></li><li><a class="nounderline abstract_t">Reis SE, Holubkov R, Lee JS, et al. Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of the Women's Ischemia Syndrome Evaluation (WISE) study. J Am Coll Cardiol 1999; 33:1469.</a></li><li><a class="nounderline abstract_t">Ohba K, Sugiyama S, Sumida H, et al. Microvascular coronary artery spasm presents distinctive clinical features with endothelial dysfunction as nonobstructive coronary artery disease. J Am Heart Assoc 2012; 1:e002485.</a></li><li><a class="nounderline abstract_t">Ong P, Athanasiadis A, Borgulya G, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation 2014; 129:1723.</a></li><li><a class="nounderline abstract_t">Ciliberti G, Seshasai SRK, Ambrosio G, Kaski JC. Safety of intracoronary provocative testing for the diagnosis of coronary artery spasm. Int J Cardiol 2017; 244:77.</a></li><li><a class="nounderline abstract_t">Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. Circulation 2017; 135:1075.</a></li><li><a class="nounderline abstract_t">Taylor CA, Fonte TA, Min JK. Computational fluid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional flow reserve: scientific basis. J Am Coll Cardiol 2013; 61:2233.</a></li><li><a class="nounderline abstract_t">Hulten E, Di Carli MF. FFRCT: Solid PLATFORM or Thin Ice? J Am Coll Cardiol 2015; 66:2324.</a></li><li><a class="nounderline abstract_t">Thomson LE, Wei J, Agarwal M, et al. Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women's Ischemia Syndrome Evaluation. Circ Cardiovasc Imaging 2015; 8.</a></li><li><a class="nounderline abstract_t">Lanza GA, Buffon A, Sestito A, et al. Relation between stress-induced myocardial perfusion defects on cardiovascular magnetic resonance and coronary microvascular dysfunction in patients with cardiac syndrome X. J Am Coll Cardiol 2008; 51:466.</a></li><li><a class="nounderline abstract_t">Galiuto L, Sestito A, Barchetta S, et al. Noninvasive evaluation of flow reserve in the left anterior descending coronary artery in patients with cardiac syndrome X. Am J Cardiol 2007; 99:1378.</a></li><li><a class="nounderline abstract_t">Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol 2018; 250:16.</a></li><li><a class="nounderline abstract_t">Radico F, Cicchitti V, Zimarino M, De Caterina R. Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease: practical considerations for diagnostic tests. JACC Cardiovasc Interv 2014; 7:453.</a></li><li><a class="nounderline abstract_t">Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018; 39:840.</a></li><li><a class="nounderline abstract_t">Jespersen L, Hvelplund A, Abildstrøm SZ, et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J 2012; 33:734.</a></li><li><a class="nounderline abstract_t">AlBadri A, Bairey Merz CN, Johnson BD, et al. Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes in Women. J Am Coll Cardiol 2019; 73:684.</a></li><li><a class="nounderline abstract_t">Gupta A, Taqueti VR, van de Hoef TP, et al. Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease. Circulation 2017; 136:2325.</a></li><li><a class="nounderline abstract_t">Larsen AI, Galbraith PD, Ghali WA, et al. Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 2005; 95:261.</a></li><li><a class="nounderline abstract_t">Shimokawa H, Suda A, Takahashi J, et al. Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur Heart J 2021; 42:4592.</a></li><li><a class="nounderline abstract_t">Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995; 25:333.</a></li><li><a class="nounderline abstract_t">Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol 1999; 84:854.</a></li><li><a class="nounderline abstract_t">Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 1994; 23:652.</a></li><li><a class="nounderline abstract_t">Pauly DF, Johnson BD, Anderson RD, et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Am Heart J 2011; 162:678.</a></li><li><a class="nounderline abstract_t">Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity. Circulation 2004; 109:53.</a></li><li><a class="nounderline abstract_t">Kayikcioglu M, Payzin S, Yavuzgil O, et al. Benefits of statin treatment in cardiac syndrome-X1. Eur Heart J 2003; 24:1999.</a></li><li><a class="nounderline abstract_t">Bugiardini R, Manfrini O, Pizzi C, et al. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 2004; 109:2518.</a></li><li><a class="nounderline abstract_t">Bugiardini R, Borghi A, Biagetti L, Puddu P. Comparison of verapamil versus propranolol therapy in syndrome X. Am J Cardiol 1989; 63:286.</a></li><li><a class="nounderline abstract_t">Fragasso G, Chierchia SL, Pizzetti G, et al. Impaired left ventricular filling dynamics in patients with angina and angiographically normal coronary arteries: effect of beta adrenergic blockade. Heart 1997; 77:32.</a></li><li><a class="nounderline abstract_t">Madaric J, Bartunek J, Verhamme K, et al. Hyperdynamic myocardial response to beta-adrenergic stimulation in patients with chest pain and normal coronary arteries. J Am Coll Cardiol 2005; 46:1270.</a></li><li><a class="nounderline abstract_t">Masumoto A, Mohri M, Takeshita A. Three-year follow-up of the Japanese patients with microvascular angina attributable to coronary microvascular spasm. Int J Cardiol 2001; 81:151.</a></li><li><a class="nounderline abstract_t">Mehta PK, Goykhman P, Thomson LE, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging 2011; 4:514.</a></li><li><a class="nounderline abstract_t">Villano A, Di Franco A, Nerla R, et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol 2013; 112:8.</a></li><li><a class="nounderline abstract_t">Cannon RO 3rd, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330:1411.</a></li><li><a class="nounderline abstract_t">Cox ID, Hann CM, Kaski JC. Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J 1998; 19:250.</a></li><li><a class="nounderline abstract_t">Jadhav S, Ferrell W, Greer IA, et al. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2006; 48:956.</a></li><li><a class="nounderline abstract_t">Khan JN, Patel N, Steeds R, Varma C. Sildenafil: a novel therapy in the management of cardiac syndrome X. N Z Med J 2012; 125:101.</a></li><li><a class="nounderline abstract_t">Lanza GA, Sestito A, Sgueglia GA, et al. Effect of spinal cord stimulation on spontaneous and stress-induced angina and 'ischemia-like' ST-segment depression in patients with cardiac syndrome X. Eur Heart J 2005; 26:983.</a></li><li><a class="nounderline abstract_t">Lanza GA, Sestito A, Sandric S, et al. Spinal cord stimulation in patients with refractory anginal pain and normal coronary arteries. Ital Heart J 2001; 2:25.</a></li><li><a class="nounderline abstract_t">Kronhaus KD, Lawson WE. Enhanced external counterpulsation is an effective treatment for Syndrome X. Int J Cardiol 2009; 135:256.</a></li><li><a class="nounderline abstract_t">Giannini F, Baldetti L, Ielasi A, et al. First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease. JACC Cardiovasc Interv 2017; 10:1901.</a></li></ol></div><div id="topicVersionRevision">Topic 1479 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32626906" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology&amp;Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17314342" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Coronary microvascular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2188757" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Coronary artery spasm and vasoconstriction. The case for a distinction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9643687" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Angina pectoris caused by coronary microvascular spasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25075937" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Coronary microvascular spasm triggers transient ischemic left ventricular diastolic abnormalities in patients with chest pain and angiographically normal coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11869851" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34459240" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anxiety Disorders Are Associated With Coronary Endothelial Dysfunction in Women With Chest Pain and Nonobstructive Coronary Artery Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27591223" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Coronary microvascular dysfunction after long-term diabetes and hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20579539" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31193994" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742283" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19502228" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34172829" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Epicardial adipose tissue differentiates in patients with and without coronary microvascular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25634404" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Etiopathogenesis of microvascular angina: caveats in our knowledge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8436742" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Delayed recovery of coronary resistive vessel function after coronary angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366916" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Coronary microvascular dysfunction: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165580" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34160566" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10610629" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Systemic amyloidosis presenting with angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10974179" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12075053" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Myocardial ischemia and the pains of the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769677" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9014980" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Investigation of the mechanism of chest pain in patients with angiographically normal coronary arteries using transesophageal dobutamine stress echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9388095" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of left ventricular function and volumes during transesophageal atrial pacing combined with two-dimensional echocardiography in patients with syndrome X, atherosclerotic coronary artery disease, and normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1939947" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Absence of myocardial dysfunction during stress in patients with syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8026038" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3122985" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Is altered cardiac sensation responsible for chest pain in patients with normal coronary arteries? Clinical observation during cardiac catheterisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7869561" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The sensitive heart. A syndrome of abnormal cardiac pain perception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9842013" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Role of the central endogenous opiate system in patients with syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35301851" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8173366" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chest pain in women: clinical, investigative, and prognostic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7884081" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24787469" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effects of sex on coronary microvascular dysfunction and cardiac outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727587" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15197152" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11320360" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15950577" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Brachial artery flow-mediated dilation and myocardial perfusion in patients with cardiac syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169365" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Angiographic evaluation of myocardial perfusion in patients with syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334408" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433695" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267320" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prognostic significance of dyspnea in patients referred for cardiac stress testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3788814" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Transient myocardial ischemia during daily life in patients with syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11079667" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Physical training in Syndrome X: physical training counteracts deconditioning and pain in Syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31345648" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Women with coronary microvascular dysfunction and no obstructive coronary artery disease have reduced exercise capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832004" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8074033" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10973837" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12495392" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Benefit of an early invasive management strategy in women with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475181" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024726" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Ischemic-like ST-segment changes during Holter monitoring in patients with angina pectoris and normal coronary arteries but negative exercise testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024726" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ischemic-like ST-segment changes during Holter monitoring in patients with angina pectoris and normal coronary arteries but negative exercise testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34955448" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1537124" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pathophysiological dilemma of syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8909903" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : High prevalence of the thallium-201 reverse redistribution phenomenon in patients with syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12075055" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3965167" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Left ventricular dysfunction in patients with angina pectoris, normal epicardial coronary arteries, and abnormal vasodilator reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381774" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effects of nitroglycerin on the coronary microcirculation in normal and ischemic myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14972422" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Validation of coronary flow reserve measurements by thermodilution in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712205" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334410" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of the Women's Ischemia Syndrome Evaluation (WISE) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23316292" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Microvascular coronary artery spasm presents distinctive clinical features with endothelial dysfunction as nonobstructive coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24573349" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28622945" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety of intracoronary provocative testing for the diagnosis of coronary artery spasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28289007" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23562923" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Computational fluid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional flow reserve: scientific basis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26475206" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : FFRCT: Solid PLATFORM or Thin Ice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25801710" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women's Ischemia Syndrome Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222358" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Relation between stress-induced myocardial perfusion defects on cardiovascular magnetic resonance and coronary microvascular dysfunction in patients with cardiac syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493464" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Noninvasive evaluation of flow reserve in the left anterior descending coronary artery in patients with cardiac syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29031990" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : International standardization of diagnostic criteria for microvascular angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24746648" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease: practical considerations for diagnostic tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29293969" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911339" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30765035" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28864442" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15642564" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34038937" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7829785" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10513787" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113548" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21982660" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14699004" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14613735" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Benefits of statin treatment in cardiac syndrome-X1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136498" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643845" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparison of verapamil versus propranolol therapy in syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9038691" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Impaired left ventricular filling dynamics in patients with angina and angiographically normal coronary arteries: effect of beta adrenergic blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16198842" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hyperdynamic myocardial response to beta-adrenergic stimulation in patients with chest pain and normal coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11744131" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Three-year follow-up of the Japanese patients with microvascular angina attributable to coronary microvascular spasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21565740" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23558043" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8159194" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Imipramine in patients with chest pain despite normal coronary angiograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9519318" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16949486" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22472718" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Sildenafil: a novel therapy in the management of cardiac syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15642701" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effect of spinal cord stimulation on spontaneous and stress-induced angina and 'ischemia-like' ST-segment depression in patients with cardiac syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11214698" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Spinal cord stimulation in patients with refractory anginal pain and normal coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18590931" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Enhanced external counterpulsation is an effective treatment for Syndrome X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28935084" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
